USA

Isomorphic Labs plans to use the new capital to further develop and deploy its proprietary AI drug design engine, known as IsoDDE.

The acquisition will give Zydus access to Assertio’s commercial infrastructure in the US specialty pharmaceutical market, particularly in oncology supportive care and pain management therapies.

The acquisition follows Stryker’s earlier move into the vascular intervention market through its approximately US$4.9 billion purchase of Inari Medical in 2025.

The new 250,000-square-foot (23,226-square-metre) Bellwether Laboratory will significantly expand global production capacity for actinium-225 (Ac-225).

The Denton facility will become Novartis’ first manufacturing site in Texas and its fifth radioligand therapy production site in the country.

Urodynamics assesses how the bladder, urethra, and sphincters store and release urine to identify causes of leakage or obstruction.

The acquisition builds on an established collaboration between Roche and PathAI that began in 2021 and expanded in 2024 to include the development of AI-enabled companion diagnostic algorithms.

Catalyst Pharmaceuticals, listed on Nasdaq in 2006, has evolved into a focused rare disease company with strong commercial momentum.

The robot-assisted technologies under this agreement respond directly to this challenge by improving clinical outcomes and reducing procedural complications.

The additional funding will enhance two key facilities within the Lebanon complex, known collectively as the LEAP Research and Innovation District.